Kevin Se Ball

[Kevin Se Ball @KevinSeBall]

@aleabitoreddit #ONT major investors holding. Can move big on small volume

[Kevin Se Ball @KevinSeBall]

@aleabitoreddit Long #ONT $ONT

[Kevin Se Ball @KevinSeBall]

Security for the PTAs: In exchange for the financial relief, Mobico's German subsidiary is reportedly being obligated to continue operating the trains even in the event of a future sale of the business.

We will also now be a takeover target. 80-100p

[Kevin Se Ball @KevinSeBall]

#MCG Mobico
​Contract Changes:
​Loss-making lines (RB48 and RE7): These contracts will be shortened, ending in 2027 instead of 2030, allowing Mobico/National Express to exit these unprofitable services earlier.

[Kevin Se Ball @KevinSeBall]

Cost of the Deal: The settlement will cost the German transport authorities significantly more than €200 million.

​Contract Changes:
Profitable RRX lines: These contracts will be extended until 2035, providing long-term revenue stability.

[Kevin Se Ball @KevinSeBall]

#AVCT #FUM #GDR #NFX #HEMO #ARCM #ORCP #TUN #ARB #MATD #GST #GGP #ONDO #SAR #KOD #FTSE #CTL #TRP #AIM #CPX #EUA#AT

MAJOR SHORT SQUEEZE COMING ON ASHTEAD TECHNOLOGY AT.

[Kevin Se Ball @KevinSeBall]

$CWR Buy Case: The ARM of Energy is Now the AI Power Play 🚀
​The thesis is simple: Ceres is an IP licensing machine (like $ARM), not a factory builder. High-margin royalties are the game.
​#CeresPower #CleanEnergy #Hydrogen #AIPower $CWR

[Kevin Se Ball @KevinSeBall]

@RebelHQ #CWR Has alot of catching up to do with BE.

[Kevin Se Ball @KevinSeBall]

#cwr
Has some catching up to do with BE

[Kevin Se Ball @KevinSeBall]

🔥 #ASHTEADTECHNOLOGY (AT.) 🚀
Ashtead Technology Holdings PLC Significant upside with their 12-month price target ,725.00p
​​Current price is around 327.50p. The "BUY" consensus is driven by strong earnings and revenue growth forecasts. #AT. #StockMarket #Investment #UKStocks

[Kevin Se Ball @KevinSeBall]

@ZaksTradersCafe KEFI target price of only 2.5p is going to get smashed with news imminent

[Kevin Se Ball @KevinSeBall]

#Renx #Imm #Avct #Hemo #alrt

Renalytix RENX. Golden Cross formed yesterday on chart.. Very Bullish...

[Kevin Se Ball @KevinSeBall]

#renx #avct #imm #hemo
Renalytix plc
Presentation is up - look at those potentials

Exceeding 20% target of last year

Estimated revenue potential in NY $754 mill

Texas - $1.3 billion

Florida - $921 mil

https://t.co/YEcJL4YnyH.

[Kevin Se Ball @KevinSeBall]

#renx #avct #imm #hemo
RNS.. Renalytix
Investor Presentation and Revised Revenue Guidance.

Revised forward guidance on expected long-term increase in revenue.

Excellent news...

[Kevin Se Ball @KevinSeBall]

#Renx Reaching 250,000 primary care physicians via Tempus no doubt. RENX could only dream of that penetration before Tempus came along. What a deal! It looks like we have a bottom price of 9,5P now and the scope for upward movement looks eye watering.What an opportunity BUY

[Kevin Se Ball @KevinSeBall]

#Renx Renalytix PLC RENX, collaboration with multimillion dollar company.
Multibagger no doubt $950 per test approved by Medicare 15 million patients in US.

[Kevin Se Ball @KevinSeBall]

#AVCT #FUM #GDR #NFX #HEMO #ARCM #ORCP #TUN #ARB #MATD #GST #GGP #ONDO #SAR #KOD #FTSE #CTL #TRP #AIM #CPX #EUA #QED#imm
#RENX Renalytix is going to rerate. Collaboration with multimillion dollar AI company.
https://t.co/WhfAZ2f8xp

[Kevin Se Ball @KevinSeBall]

@renalytix's partnership with @TempusAI is a game-changer.#Renx
​By integrating its FDA-approved kidney test into Tempus's vast network of over 2,000 healthcare institutions, gets a powerful distribution channel. This move could fast-track test adoption and accelerate revenue.

[Kevin Se Ball @KevinSeBall]

@renalytix's partnership with @TempusAI is a game-changer.
​By integrating its FDA-approved kidney test into Tempus's vast network of over 2,000 healthcare institutions, #RNLX gets a powerful distribution channel. This move could fast-track test adoption and accelerate revenue.

[Kevin Se Ball @KevinSeBall]

#imm #Renx
Renx next Imm
With the Tempus Ai news, really do feel Renalytix is about to go on an unbelievable run. Consensus target from 5 analysts is 86p-91p.

Many companies have 5-10x on nothing. Renx have growing revenues, which are about to be turbo charged.